Trial Profile

A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant ("Transplant Noneligible" [TNE])

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Bortezomib
Indications Adenocarcinoma; Bladder cancer; Cholangiocarcinoma; Lung cancer; Multiple myeloma; Prostate cancer; Renal cell carcinoma; Skin cancer
Focus Adverse reactions
Sponsors Celgene Corporation

28 May 2026 Status changed from active, no longer recruiting to completed.
24 Nov 2025 Planned primary completion date changed from 19 Oct 2025 to 12 Dec 2025.
15 Jul 2025 Planned primary completion date changed from 13 Jul 2024 to 19 Oct 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com